$RENE
Cartesian Growth Corporation II

2022 Q1 Form 10-Q Financial Statement

#000156459022023565 Filed on June 17, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $0.00
YoY Change
Operating Profit $0.00 -$3.727K
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income $0.00
YoY Change
Income Tax
% Of Pretax Income
Net Earnings $0.00 -$3.727K
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 5.000M 5.750M
Diluted Shares Outstanding 5.000M 5.750M

Balance Sheet

Concept 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $0.00
Short-Term Investments
Other Short-Term Assets $567.6K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $567.6K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$2.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $567.6K
Total Long-Term Assets -$2.00
Total Assets $567.6K $463.6K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $344.9K $303.9K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $201.4K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $546.3K $442.4K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $546.3K $442.4K
Total Long-Term Liabilities $0.00
Total Liabilities $546.3K $442.4K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$3.727K -$3.727K
YoY Change
Common Stock $24.43K $24.43K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.27K $21.27K
YoY Change
Total Liabilities & Shareholders Equity $567.6K $463.6K
YoY Change

Cashflow Statement

Concept 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income $0.00 -$3.727K
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $0.00 $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities 0.000 0.000
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000 0.000
Net Change In Cash 0.000 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities $0.00 $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 reneu Deferred Offering Costs Included In Accrued Offering Costs
DeferredOfferingCostsIncludedInAccruedOfferingCosts
78229
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 reneu Percentage Of Fair Market Value Of Assets Held In Trust Account
PercentageOfFairMarketValueOfAssetsHeldInTrustAccount
0.80
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001889112
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5000000
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-41378
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Cartesian Growth Corporation II
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
505 Fifth Avenue
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
15th Floor
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
CY2022Q1 dei City Area Code
CityAreaCode
212
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
461-6363
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
true
CY2022Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
567608
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
463629
CY2022Q1 us-gaap Assets
Assets
567608
CY2021Q4 us-gaap Assets
Assets
463629
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
344930
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
303895
CY2022Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
201405
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
138461
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
546335
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
442356
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
0
CY2022Q1 reneu Common Stock Value1
CommonStockValue1
575
CY2021Q4 reneu Common Stock Value1
CommonStockValue1
575
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
24425
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
21273
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
24425
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3727
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3727
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
21273
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21273
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21273
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
62944
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
62944
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
0
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
567608
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
463629
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5000000
CY2022Q1 reneu Percentage Of Voting Securities
PercentageOfVotingSecurities
0.50
CY2022Q1 reneu Public Share Price Per Share
PublicSharePricePerShare
10.30
CY2022Q1 us-gaap Interest Expense Other
InterestExpenseOther
100000
CY2022Q1 reneu Public Share Price Per Share
PublicSharePricePerShare
10.30
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p>
CY2022Q1 reneu Ordinary Shares Subject To Possible Redemption
OrdinarySharesSubjectToPossibleRedemption
0
CY2021Q4 reneu Ordinary Shares Subject To Possible Redemption
OrdinarySharesSubjectToPossibleRedemption
0
CY2022Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
567608
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
463629
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. As of March 31, 2022 and December 31, 2021, the Company has not experienced losses on its accounts.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </p>
CY2022Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q1 us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Derivative Financial Instruments</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging” (“ASC 815-40”). The Company’s derivative instruments are recorded at fair value on the balance sheets with changes in the fair value reported in the statement of operations. Derivative assets and liabilities are classified on the balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheets date.</p>
CY2022Q1 reneu Warrant Description
WarrantDescription
The warrants will become exercisable on the later of 12 months from the closing of the Initial Public Offering or 30 days after the completion of the Company’s initial Business Combination, and will expire five years after the completion of the Company’s initial Business Combination, or earlier upon redemption or liquidation.
CY2021Q4 us-gaap Sponsor Fees
SponsorFees
25000
CY2021Q4 reneu Price Per Share Unit
PricePerShareUnit
0.004
CY2021Q4 reneu Assets Tangible And Intangible
AssetsTangibleAndIntangible
0
CY2021Q4 reneu Percentage Of Founder Shares
PercentageOfFounderShares
0.20
CY2022Q1 reneu Business Combination Description
BusinessCombinationDescription
The Sponsor and directorCo have agreed not to transfer, assign or sell any of the founder shares (except to certain permitted transferees) until one year after the date of the completion of the initial Business Combination or earlier if, subsequent to the initial Business Combination, (i) the last reported sale price of the Class A Ordinary Shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (ii) the Company consummates a subsequent liquidation, merger, share exchange or other similar transaction which results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property.
CY2022Q1 reneu Office Space Monthly Rent
OfficeSpaceMonthlyRent
10000
CY2022Q1 reneu Working Capital Loan
WorkingCapitalLoan
1500000
CY2022Q1 reneu Price Per Warrant
PricePerWarrant
1.00
CY2022Q1 reneu Registration Rights Description
RegistrationRightsDescription
The holders of the majority of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lock-up period, which occurs (i) in the case of the founder shares, one year after the date of the completion of the initial Business Combination or earlier if, subsequent to the initial Business Combination, the last reported sale price of the Class A Ordinary Shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or the Company consummates a subsequent liquidation, merger, share exchange or other similar transaction which results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (ii) in the case of the Private Placement Warrants and the respective Class A Ordinary Shares underlying such Private Placement Warrants, 30 days after the completion of the initial Business Combination.
CY2022Q1 reneu Deferred Underwriting Discount
DeferredUnderwritingDiscount
0.50
CY2022Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
11500000
CY2022Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
16566666
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Sale Of Stock Percentage Of Ownership Before Transaction
SaleOfStockPercentageOfOwnershipBeforeTransaction
0.20
CY2022Q1 us-gaap Sale Of Stock Percentage Of Ownership Before Transaction
SaleOfStockPercentageOfOwnershipBeforeTransaction
0.20

Files In Submission

Name View Source Status
0001564590-22-023565-index-headers.html Edgar Link pending
0001564590-22-023565-index.html Edgar Link pending
0001564590-22-023565.txt Edgar Link pending
0001564590-22-023565-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
reneu-10q_20220331.htm Edgar Link pending
reneu-10q_20220331_htm.xml Edgar Link completed
reneu-20220331.xsd Edgar Link pending
reneu-20220331_cal.xml Edgar Link unprocessable
reneu-20220331_def.xml Edgar Link unprocessable
reneu-20220331_lab.xml Edgar Link unprocessable
reneu-20220331_pre.xml Edgar Link unprocessable
reneu-ex311_9.htm Edgar Link pending
reneu-ex312_8.htm Edgar Link pending
reneu-ex321_6.htm Edgar Link pending
reneu-ex322_7.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending